HCV不同编码区抗体在慢性丙型肝炎干扰素治疗中的变化

THE CHANGES OF ANTIBODIES AGAINST RECOMBINANT ANTIGENS ENCODED BY DIFFERENT REGIONS OF HCV GENOME IN PATIENTS WITH CHRONIC HEPATITIS C

采用含ＨＣＶ不同编码区三种重组抗原（Ｃ２２，Ｃ３３ｃ，Ｃ１００－３）的重组免疫印迹试验，对２０例接受干扰素（ＩＦＮ）治疗的慢性丙型肝炎患者血清相应的三种抗体进行动态监测，同时观察ＨＣＶＲＮＡ及ＡＬＴ的变化，并进行对比分析。结果表明：ＨＣＶＲＮＡ持续清除与Ｃ３３ｃ及Ｃ１００－３抗体滴度的持续下降及转阴有关（Ｐ值分别＜０．０１及＜０．００５），与Ｃ２２抗体变化无关（Ｐ＞０．０５）；ＩＦＮ治疗后ＡＬＩ稳定正常与ＨＣＶ病毒血症清除之间无相关性（Ｐ＞０．０５）。提示动态观察抗－Ｃ１００－３及抗－Ｃ３３ｃ可预测ＣＨＣ病人ＩＦＮ治疗后病毒血症的变化，而ＩＦＮ治疗后ＡＬＴ转为稳定正常不一定预示病毒血症消失。

Twenty patients with chronic hepatitis C were investigated during the treatment with interferon to explore the changes of antibodies to HCV(anti-HCV). Anti-HCV was tested by recombinant immunoblot assay (RIBA) with three antigens (C22,C33c, and C100-3) encoded by different regions of HCV genome. The changes of individual anti-HCV and ALT were compared with those of HCV RNA. The results show that persistant disappearance of serum HCV RNA is closely related to the changes of anti-C33 (P<0.01) and anti-C100-3(P<0.005), but there is no relation between persistant ALT normality and HCV viremia clearance (P>0.05). In conclusion, monitoring anti-C33c and anti-C100-3 can deduce the change of HCV viremia. The normalization of ALT after interferon treatment does notindicate disappear of HCV viremia.